INVECTYS, INC. TO PARTICIPATE IN THE 41st JP MORGAN HEALTHCARE CONFERENCE ON JANUARY 9-12, 2023 Houston, Texas, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Invectys, Inc. “Invectys”, a clinical-stage immunotherapy company headquartered in Houston and dedicated to the development of a new generation of...

Wayne A. Marasco, M.D., Ph.D. joins Invectys’ Scientific Advisory Board Houston, Texas, USA, March 09, 2022 (GLOBE NEWSWIRE) -- Invectys, Inc. of Houston, Texas, a clinical stage immunotherapy company dedicated to the development of a next generation of therapies to...

Invectys appoints Jian Cao, Ph.D., as Vice President, Pharmaceutical Development Houston, Texas, USA, March 01, 2022 (GLOBE NEWSWIRE) -- Invectys, Inc. of Houston, Texas, a clinical stage immunotherapy company dedicated to the development of a next generation of therapies to...

INVECTYS INC. TO PARTICIPATE IN THE 2022 JP MORGAN HEALTHCARE MEETING AND BIOTECH SHOWCASE, JANUARY 10-19, 2022  Houston, Texas, USA, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Invectys Inc. a clinical-stage immunotherapy company headquartered in Houston and dedicated to the development of a new generation of products...

INmune Bio to Present at BIO CEO & Investor Conference LA JOLLA, CA, Feb. 06, 2019 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (Nasdaq: INMB) (“INmune” or the “Company”), an immunotherapy company focused on developing therapies that harness the patient’s...